Cryo-Cell (CCEL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$31.1M

Revenue (quarter)

$7.8M

Revenue growth (year over year)

−0.02%

Gross profit (trailing twelve months)

$24.4M

Gross margin

78.54%

Net income (trailing twelve months)

−$1.9M

Net income (quarter)

$1.3M

Net income growth (year over year)

+69.53%

Net margin

−6.25%

Return on equity

—

EPS (trailing twelve months)

−$0.24

Book value per share

−$2.03

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

126.31%

Payout ratio

−133.07%

Dividend yield

3.63%

Company profile

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

• Is Cryo-Cell (CCEL) profitable?

  No. Cryo-Cell reported a net loss of $1.9M over the trailing twelve months.

• How much revenue does Cryo-Cell (CCEL) make?

  Cryo-Cell generated $31.1M in revenue over the trailing twelve months, down 0.02% year over year.

• How do I buy stock in Cryo-Cell (CCEL)?

  CCEL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.